Table 2.
Dose escalation of irinotecan and observed DLTs in patients treated with FOLFIRI plus bevacizumab.
Irinotecan dose (mg/m2) | *1/*1 patients (DLTs) | *1/*28 patients (DLTs) |
---|---|---|
260 | 10 (1) Grade 3 diarrhea |
10 (2) Grade 3 arrythmia Grade 4 neutropenia |
310 | 10 (2) Grade 3 diarrhea x 2 |
10 (4) Grade 3 diarrhea Grade 3 mucositis Grade 4 neutropenia x 2 |
370 | 4 (2) Grade 3 nausea/vomiting Grade 5 neutropenic sepsis |
3 (2) Grade 3 diarrhea Grade 4 neutropenia x 2 |